Lantheus (NASDAQ:LNTH) issued its earnings results on Tuesday. The medical equipment provider reported $0.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.06, MarketWatch Earnings reports. The company had revenue of $92.51 million during the quarter, compared to the consensus estimate of $87.24 million. Lantheus had a return on equity of 11.05% and a net margin of 0.12%. The firm’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period last year, the business posted $0.36 EPS.
Shares of NASDAQ:LNTH traded down $0.69 during mid-day trading on Tuesday, reaching $22.99. The company had a trading volume of 9,492 shares, compared to its average volume of 551,996. The company has a current ratio of 2.25, a quick ratio of 1.79 and a debt-to-equity ratio of 0.40. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of 297.41 and a beta of 1.32. The company’s 50-day moving average price is $21.19 and its 200-day moving average price is $16.69. Lantheus has a one year low of $10.52 and a one year high of $24.20.
In other Lantheus news, Director Sam R. Leno sold 5,000 shares of the business’s stock in a transaction on Thursday, April 8th. The shares were sold at an average price of $21.17, for a total transaction of $105,850.00. Following the sale, the director now owns 40,784 shares of the company’s stock, valued at approximately $863,397.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael P. Duffy sold 7,500 shares of the business’s stock in a transaction on Friday, April 16th. The shares were sold at an average price of $21.75, for a total transaction of $163,125.00. Following the sale, the senior vice president now directly owns 109,472 shares in the company, valued at approximately $2,381,016. The disclosure for this sale can be found here. Insiders sold a total of 72,188 shares of company stock worth $1,411,148 in the last ninety days. 2.08% of the stock is currently owned by insiders.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation.
Read More: What is a short straddle?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.